NASDAQ:ONCR

Oncorus Competitors

$13.68
-0.48 (-3.39 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$13.00
Now: $13.68
$14.25
50-Day Range
$11.89
MA: $14.60
$16.70
52-Week Range
$11.50
Now: $13.68
$37.86
Volume206,983 shs
Average Volume166,554 shs
Market Capitalization$350.55 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Oncorus (NASDAQ:ONCR) Vs. SAVA, ACRS, ATBPD, ARQT, KROS, and CMPS

Should you be buying ONCR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Oncorus, including Cassava Sciences (SAVA), Aclaris Therapeutics (ACRS), Antibe Therapeutics (ATBPD), Arcutis Biotherapeutics (ARQT), Keros Therapeutics (KROS), and COMPASS Pathways (CMPS).

Oncorus (NASDAQ:ONCR) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oncorus and Cassava Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncorus00403.00
Cassava Sciences00403.00

Oncorus presently has a consensus price target of $33.00, suggesting a potential upside of 141.23%. Cassava Sciences has a consensus price target of $35.3333, suggesting a potential upside of 1.39%. Given Oncorus' higher possible upside, equities research analysts clearly believe Oncorus is more favorable than Cassava Sciences.

Institutional & Insider Ownership

26.7% of Cassava Sciences shares are held by institutional investors. 13.7% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Oncorus and Cassava Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncorusN/AN/A$-30,700,000.00N/AN/A
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-129.07

Profitability

This table compares Oncorus and Cassava Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OncorusN/AN/AN/A
Cassava SciencesN/A-22.01%-20.85%

Oncorus (NASDAQ:ONCR) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oncorus and Aclaris Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncorus00403.00
Aclaris Therapeutics0000N/A

Oncorus presently has a consensus price target of $33.00, suggesting a potential upside of 141.23%. Given Oncorus' higher possible upside, equities research analysts clearly believe Oncorus is more favorable than Aclaris Therapeutics.

Institutional & Insider Ownership

59.1% of Aclaris Therapeutics shares are held by institutional investors. 8.2% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Oncorus and Aclaris Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncorusN/AN/A$-30,700,000.00N/AN/A
Aclaris Therapeutics$4.23 million326.74$-161,350,000.00($2.25)-11.86

Oncorus has higher earnings, but lower revenue than Aclaris Therapeutics.

Profitability

This table compares Oncorus and Aclaris Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OncorusN/AN/AN/A
Aclaris Therapeutics-941.07%-104.00%-64.47%

Summary

Oncorus beats Aclaris Therapeutics on 6 of the 9 factors compared between the two stocks.

Oncorus (NASDAQ:ONCR) and Antibe Therapeutics (NASDAQ:ATBPD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oncorus and Antibe Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncorus00403.00
Antibe Therapeutics0000N/A

Oncorus presently has a consensus price target of $33.00, suggesting a potential upside of 141.23%. Given Oncorus' higher possible upside, equities research analysts clearly believe Oncorus is more favorable than Antibe Therapeutics.

Valuation & Earnings

This table compares Oncorus and Antibe Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncorusN/AN/A$-30,700,000.00N/AN/A
Antibe Therapeutics$7.51 million183.97$-14,540,000.00($0.50)-7.14

Antibe Therapeutics has higher revenue and earnings than Oncorus.

Profitability

This table compares Oncorus and Antibe Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OncorusN/AN/AN/A
Antibe Therapeutics-273.96%-176.23%-106.91%

Summary

Oncorus beats Antibe Therapeutics on 5 of the 7 factors compared between the two stocks.

Oncorus (NASDAQ:ONCR) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oncorus and Arcutis Biotherapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncorus00403.00
Arcutis Biotherapeutics00403.00

Oncorus presently has a consensus price target of $33.00, suggesting a potential upside of 141.23%. Arcutis Biotherapeutics has a consensus price target of $54.6667, suggesting a potential upside of 98.64%. Given Oncorus' higher possible upside, equities research analysts clearly believe Oncorus is more favorable than Arcutis Biotherapeutics.

Valuation & Earnings

This table compares Oncorus and Arcutis Biotherapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncorusN/AN/A$-30,700,000.00N/AN/A
Arcutis BiotherapeuticsN/AN/A$-42,000,000.00($22.78)-1.21

Institutional & Insider Ownership

79.6% of Arcutis Biotherapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Oncorus and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OncorusN/AN/AN/A
Arcutis BiotherapeuticsN/A-81.74%-57.72%

Summary

Oncorus beats Arcutis Biotherapeutics on 4 of the 5 factors compared between the two stocks.

Oncorus (NASDAQ:ONCR) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Oncorus and Keros Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncorus00403.00
Keros Therapeutics00403.00

Oncorus currently has a consensus price target of $33.00, suggesting a potential upside of 141.23%. Keros Therapeutics has a consensus price target of $78.00, suggesting a potential upside of 37.64%. Given Oncorus' higher possible upside, research analysts plainly believe Oncorus is more favorable than Keros Therapeutics.

Valuation and Earnings

This table compares Oncorus and Keros Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncorusN/AN/A$-30,700,000.00N/AN/A
Keros TherapeuticsN/AN/AN/AN/AN/A

Institutional and Insider Ownership

58.4% of Keros Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Oncorus and Keros Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OncorusN/AN/AN/A
Keros TherapeuticsN/AN/AN/A

Oncorus (NASDAQ:ONCR) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Oncorus and COMPASS Pathways, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncorus00403.00
COMPASS Pathways00603.00

Oncorus currently has a consensus price target of $33.00, suggesting a potential upside of 141.23%. COMPASS Pathways has a consensus price target of $70.75, suggesting a potential upside of 105.97%. Given Oncorus' higher possible upside, research analysts plainly believe Oncorus is more favorable than COMPASS Pathways.

Valuation and Earnings

This table compares Oncorus and COMPASS Pathways' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncorusN/AN/A$-30,700,000.00N/AN/A
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A

Institutional and Insider Ownership

15.8% of COMPASS Pathways shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Oncorus and COMPASS Pathways' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OncorusN/AN/AN/A
COMPASS PathwaysN/AN/AN/A

Summary

COMPASS Pathways beats Oncorus on 3 of the 4 factors compared between the two stocks.


Oncorus Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85-0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68-1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
Gap Down
ATBPD
Antibe Therapeutics
0.1$3.57-0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52-4.2%$1.38 billionN/A-2.98Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67-12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35-0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01-5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68-1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89-1.6%$1.21 billion$4.23 million-8.88Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56-0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16-1.7%$1.17 billion$59.70 million-191.60Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55-0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01-0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65-3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
Gap Down
NKTX
Nkarta
1.8$34.87-5.2%$1.14 billionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22-4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Gap Down
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91-6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59Gap Down
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Gap Down
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$27.37-5.6%$1.06 billionN/A0.00Increase in Short Interest
Lockup Expiration
News Coverage
MannKind logo
MNKD
MannKind
1.4$4.18-2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Gap Down
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.98-4.0%$1.03 billion$120,000.00-3.70Analyst Report
News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.68-2.1%$1.02 billion$122.47 million-27.85Analyst Downgrade
News Coverage
Prothena logo
PRTA
Prothena
2.1$24.85-3.2%$994.15 million$810,000.00-9.71Increase in Short Interest
News Coverage
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.71-5.2%$989.07 millionN/A-6.48Increase in Short Interest
News Coverage
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.43-1.1%$988.27 million$800.40 million23.05
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.51-6.8%$986.46 millionN/A-8.11Insider Selling
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$20.41-2.8%$984.50 million$1.52 million-10.86Increase in Short Interest
News Coverage
Gap Down
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.34-1.0%$950.61 millionN/A-12.60
Radius Health logo
RDUS
Radius Health
1.1$19.71-0.2%$924.28 million$173.32 million-8.08
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67-0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.45-0.5%$897.94 millionN/A0.00
Annexon logo
ANNX
Annexon
1.9$23.42-2.2%$893.66 millionN/A0.00Increase in Short Interest
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$34.95-0.1%$858.83 millionN/A-10.37Analyst Report
News Coverage
Merus logo
MRUS
Merus
1.6$22.52-1.7%$858.62 million$31.13 million-7.34Analyst Report
Ardelyx logo
ARDX
Ardelyx
1.6$8.69-0.3%$857.53 million$5.28 million-8.60High Trading Volume
Unusual Options Activity
News Coverage
Affimed logo
AFMD
Affimed
1.6$9.51-0.3%$839.98 million$23.96 million-16.12Earnings Announcement
Analyst Revision
News Coverage
ESSA Pharma logo
EPIX
ESSA Pharma
1.6$24.82-5.4%$838.42 millionN/A-22.98
Epizyme logo
EPZM
Epizyme
1.8$8.10-1.6%$824.46 million$23.80 million-3.63
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.30-0.3%$820.59 million$322.36 million123.57
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.27-0.8%$819.20 million$296.70 million47.49Analyst Revision
News Coverage
Humanigen logo
HGEN
Humanigen
1.7$14.73-5.6%$787.79 millionN/A0.00Increase in Short Interest
Gap Down
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.33-2.7%$782.70 millionN/A0.00Increase in Short Interest
Gap Down
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.02-0.1%$755.02 million$148.36 million-7.02Analyst Revision
News Coverage
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.